|Bid||32.57 x 800|
|Ask||32.57 x 800|
|Day's Range||32.39 - 32.93|
|52 Week Range||27.69 - 41.55|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 5, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.00|
Natus Medical Incorporated (BABY) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on October 26. Additionally, the rate of outflows appears to be accelerating.
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Natus Medical (BABY) delivered earnings and revenue surprises of -4.76% and -1.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
PLEASANTON, Calif. (AP) _ Natus Medical Inc. (BABY) on Wednesday reported a loss of $5.6 million in its third quarter. The Pleasanton, California-based company said it had a loss of 17 cents per share. The results missed Wall Street expectations.
Reports record third quarter revenue of $130.6 millionReports third quarter GAAP loss per share of $0.17 and non-GAAP earnings per share of $0.40Updates annual revenue and.
Johnson & Johnson’s (JNJ) Consumer segment consists of the baby care, beauty, oral care, OTC (over-the-counter), women’s health, and wound care businesses.
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., Oct. 10, 2018 -- Natus Medical Incorporated (NASDAQ: BABY) today announced that the Company will release its 2018 third quarter financial results before the.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on September 25. Over the last month, growth of ETFs holding BABY is favorable, with net inflows of $5.56 billion.
Natus Medical Incorporated (BABY) today announced the appointment of Drew Davies as Executive Vice-President and Chief Financial Officer, effective October 1, 2018. Mr. Davies brings nearly 30 years of financial and operational expertise to Natus. Sharon Villaverde, who has served as Interim CFO since July 11, 2018, will continue in her role as Vice President of Finance.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 23. Over the last month, ETFs holding BABY are favorable, with net inflows of $3.77 billion.
Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on August 20. Over the last month, ETFs holding BABY are favorable, with net inflows of $3.37 billion.